Literature DB >> 19768398

Pandemic influenza as a current threat.

Hui-Ling Yen1, Robert G Webster.   

Abstract

Pandemics of influenza emerge from the aquatic bird reservoir, adapt to humans, modify their severity, and cause seasonal influenza. The catastrophic Spanish H1N1 virus may have obtained all of its eight gene segments from the avian reservoir, whereas the Asian H2N2 and the Hong Kong H3N2 pandemics emerged by reassortment between the circulating human virus and an avian H2 or H3 donor. Of the 16 hemagglutinin subtypes, the H2, H5, H6, H7, and H9 viruses are considered to have pandemic potential. While this chapter focuses on the evolution of the Asian highly pathogenic (HP) H5N1 influenza virus, other subtypes are also considered. The unique features of the HP H5N1 viruses that have devastated the domestic poultry of Eurasia are discussed. Although they transmit poorly to humans, they continue to kill more than 60% of infected persons. It is unknown whether HP H5N1 will acquire human pandemic status; if it does not, another subtype eventually will do so, for a future influenza pandemic is inevitable.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19768398     DOI: 10.1007/978-3-540-92165-3_1

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  61 in total

1.  Replication-competent influenza A virus that encodes a split-green fluorescent protein-tagged PB2 polymerase subunit allows live-cell imaging of the virus life cycle.

Authors:  Sergiy V Avilov; Dorothée Moisy; Sandie Munier; Oliver Schraidt; Nadia Naffakh; Stephen Cusack
Journal:  J Virol       Date:  2011-11-23       Impact factor: 5.103

2.  Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development.

Authors:  Mariette F Ducatez; Justin Bahl; Yolanda Griffin; Evelyn Stigger-Rosser; John Franks; Subrata Barman; Dhanasekaran Vijaykrishna; Ashley Webb; Yi Guan; Robert G Webster; Gavin J D Smith; Richard J Webby
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

3.  Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine.

Authors:  Jeremy C Jones; Erik W Settles; Curtis R Brandt; Stacey Schultz-Cherry
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

4.  Trends of influenza B during the 2010-2016 seasons in 2 regions of north and south Italy: The impact of the vaccine mismatch on influenza immunisation strategy.

Authors:  Andrea Orsi; Giuseppina Maria Elena Colomba; Fanny Pojero; Giuseppe Calamusa; Cristiano Alicino; Cecilia Trucchi; Paola Canepa; Filippo Ansaldi; Francesco Vitale; Fabio Tramuto
Journal:  Hum Vaccin Immunother       Date:  2017-08-03       Impact factor: 3.452

5.  Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.

Authors:  E Bart Tarbet; Masako Maekawa; Yousuke Furuta; Y S Babu; John D Morrey; Donald F Smee
Journal:  Antiviral Res       Date:  2012-03-10       Impact factor: 5.970

6.  Parasite-mediated upregulation of NK cell-derived gamma interferon protects against severe highly pathogenic H5N1 influenza virus infection.

Authors:  Kevin B O'Brien; Stacey Schultz-Cherry; Laura J Knoll
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

7.  Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins.

Authors:  Katherine A Richards; Francisco A Chaves; Shabnam Alam; Andrea J Sant
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

8.  A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1.

Authors:  Lisette A H M Cornelissen; Robert P de Vries; Els A de Boer-Luijtze; Alan Rigter; Peter J M Rottier; Cornelis A M de Haan
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

9.  A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.

Authors:  Annett Hessel; Michael Schwendinger; Daniela Fritz; Sogue Coulibaly; Georg W Holzer; Nicolas Sabarth; Otfried Kistner; Walter Wodal; Astrid Kerschbaum; Helga Savidis-Dacho; Brian A Crowe; Thomas R Kreil; P Noel Barrett; Falko G Falkner
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

10.  Determinants of glycan receptor specificity of H2N2 influenza A virus hemagglutinin.

Authors:  Karthik Viswanathan; Xiaoying Koh; Aarthi Chandrasekaran; Claudia Pappas; Rahul Raman; Aravind Srinivasan; Zachary Shriver; Terrence M Tumpey; Ram Sasisekharan
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.